A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC), but metastatic relapse remains common. We hypothesized that the expression levels of inflammatory cytokines could predict recurrence of PDAC, thus allowing to select patients who most likely co...

Full description

Bibliographic Details
Main Authors: Geny Piro, Francesca Simionato, Carmine Carbone, Melissa Frizziero, Giuseppe Malleo, Silvia Zanini, Raffaella Casolino, Raffaela Santoro, Maria Mihaela Mina, Camilla Zecchetto, Valeria Merz, Aldo Scarpa, Claudio Bassi, Giampaolo Tortora, Davide Melisi
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:OncoImmunology
Subjects:
il4
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1322242
id doaj-200ba0274b3e406ebfd9161e5da5068f
record_format Article
spelling doaj-200ba0274b3e406ebfd9161e5da5068f2020-11-25T02:51:27ZengTaylor & Francis GroupOncoImmunology2162-402X2017-09-016910.1080/2162402X.2017.13222421322242A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinomaGeny Piro0Francesca Simionato1Carmine Carbone2Melissa Frizziero3Giuseppe Malleo4Silvia Zanini5Raffaella Casolino6Raffaela Santoro7Maria Mihaela Mina8Camilla Zecchetto9Valeria Merz10Aldo Scarpa11Claudio Bassi12Giampaolo Tortora13Davide Melisi14Università degli studi di VeronaAzienda Ospedaliera Universitaria IntegrataUniversità degli studi di VeronaAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataUniversità degli studi di VeronaUniversità degli studi di VeronaAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataAzienda Ospedaliera Universitaria IntegrataUniversità degli studi di VeronaUniversità degli studi di VeronaSurgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC), but metastatic relapse remains common. We hypothesized that the expression levels of inflammatory cytokines could predict recurrence of PDAC, thus allowing to select patients who most likely could benefit from surgical resection. We prospectively collected plasma at diagnosis from 287 patients with pancreatic resectable neoplasms. The expression levels of 23 cytokines were measured in 90 patients with PDAC by using a multiplex analyte profiling assay. Levels higher than cutoff identified of the TH2 cytokines interleukin (IL)4, IL5, IL6 of macrophage inflammatory protein (MIP)1α, granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein (MCP)1, and of IL17α, IFNγ-induced protein (IP)10, and IL1b were significantly associated with a shorter median OS. In particular, levels of IL4 and IP10 higher than cutoff identified, and level of TH1 cytokines TNFα and INFγ, and of IL9 and IL1Rα lower than cutoff identified were significantly associated with a shorter DFS. In the multivariate analysis, high IP10 was confirmed as negatively associated with OS (HR = 3.097, p = 0.014) and IL4 and TNFα remain negatively (HR = 2.75, p = 0.002) and positively (HR = 0.224, p = 0.049) associated with DFS, respectively. Simultaneous expression of low IL4 and high TNFα identified patients with best prognosis (HR = 0.313, p < 0.0001). In conclusion, we demonstrated that, among a series of cytokines, IL4 is the most significant independent prognostic factor for DFS in resectable PDAC patients, and it could be useful to select patients with high risk of early recurrence who may avoid an unnecessary resection.http://dx.doi.org/10.1080/2162402X.2017.1322242circulating cytokine profileil4pancreatic adenocarcinomaprognostic biomarkerth2 cytokines
collection DOAJ
language English
format Article
sources DOAJ
author Geny Piro
Francesca Simionato
Carmine Carbone
Melissa Frizziero
Giuseppe Malleo
Silvia Zanini
Raffaella Casolino
Raffaela Santoro
Maria Mihaela Mina
Camilla Zecchetto
Valeria Merz
Aldo Scarpa
Claudio Bassi
Giampaolo Tortora
Davide Melisi
spellingShingle Geny Piro
Francesca Simionato
Carmine Carbone
Melissa Frizziero
Giuseppe Malleo
Silvia Zanini
Raffaella Casolino
Raffaela Santoro
Maria Mihaela Mina
Camilla Zecchetto
Valeria Merz
Aldo Scarpa
Claudio Bassi
Giampaolo Tortora
Davide Melisi
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
OncoImmunology
circulating cytokine profile
il4
pancreatic adenocarcinoma
prognostic biomarker
th2 cytokines
author_facet Geny Piro
Francesca Simionato
Carmine Carbone
Melissa Frizziero
Giuseppe Malleo
Silvia Zanini
Raffaella Casolino
Raffaela Santoro
Maria Mihaela Mina
Camilla Zecchetto
Valeria Merz
Aldo Scarpa
Claudio Bassi
Giampaolo Tortora
Davide Melisi
author_sort Geny Piro
title A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
title_short A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
title_full A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
title_fullStr A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
title_full_unstemmed A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
title_sort circulating th2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
publisher Taylor & Francis Group
series OncoImmunology
issn 2162-402X
publishDate 2017-09-01
description Surgery is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC), but metastatic relapse remains common. We hypothesized that the expression levels of inflammatory cytokines could predict recurrence of PDAC, thus allowing to select patients who most likely could benefit from surgical resection. We prospectively collected plasma at diagnosis from 287 patients with pancreatic resectable neoplasms. The expression levels of 23 cytokines were measured in 90 patients with PDAC by using a multiplex analyte profiling assay. Levels higher than cutoff identified of the TH2 cytokines interleukin (IL)4, IL5, IL6 of macrophage inflammatory protein (MIP)1α, granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein (MCP)1, and of IL17α, IFNγ-induced protein (IP)10, and IL1b were significantly associated with a shorter median OS. In particular, levels of IL4 and IP10 higher than cutoff identified, and level of TH1 cytokines TNFα and INFγ, and of IL9 and IL1Rα lower than cutoff identified were significantly associated with a shorter DFS. In the multivariate analysis, high IP10 was confirmed as negatively associated with OS (HR = 3.097, p = 0.014) and IL4 and TNFα remain negatively (HR = 2.75, p = 0.002) and positively (HR = 0.224, p = 0.049) associated with DFS, respectively. Simultaneous expression of low IL4 and high TNFα identified patients with best prognosis (HR = 0.313, p < 0.0001). In conclusion, we demonstrated that, among a series of cytokines, IL4 is the most significant independent prognostic factor for DFS in resectable PDAC patients, and it could be useful to select patients with high risk of early recurrence who may avoid an unnecessary resection.
topic circulating cytokine profile
il4
pancreatic adenocarcinoma
prognostic biomarker
th2 cytokines
url http://dx.doi.org/10.1080/2162402X.2017.1322242
work_keys_str_mv AT genypiro acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT francescasimionato acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT carminecarbone acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT melissafrizziero acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT giuseppemalleo acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT silviazanini acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT raffaellacasolino acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT raffaelasantoro acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT mariamihaelamina acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT camillazecchetto acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT valeriamerz acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT aldoscarpa acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT claudiobassi acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT giampaolotortora acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT davidemelisi acirculatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT genypiro circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT francescasimionato circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT carminecarbone circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT melissafrizziero circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT giuseppemalleo circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT silviazanini circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT raffaellacasolino circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT raffaelasantoro circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT mariamihaelamina circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT camillazecchetto circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT valeriamerz circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT aldoscarpa circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT claudiobassi circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT giampaolotortora circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
AT davidemelisi circulatingth2cytokinesprofilepredictssurvivalinpatientswithresectablepancreaticadenocarcinoma
_version_ 1724734410532585472